Guilu Erxian Jiao
Phase 2Small molecule
Guilu Erxian Jiao is one of 42 small molecule programs targeting Hypotension. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Hypotension
#DrugCompanyPhaseTrials
1Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Zofran
NovartisApproved
Ephedrine Sulfate
DDr. Reddys Laboratories, SA
Approved
Proamatine
TakedaApproved
Intropin
PfizerApproved
Florinef
Jazz PharmaceuticalsApproved
Dobutrex
Eli LillyApproved
Robinul
Jazz PharmaceuticalsApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypotension1 trial
The Efficacy and Safety of Guilu Erxian Jiao in the Treatment of Intradialytic Hypotension
Not yet recruiting·—·Phase 2·NCT06980922·34 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Guilu Erxian Jiao. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CChang Gung Memorial Hospital